List of Excipients in Branded Drug TALTZ

« Back to Dashboard

Taltz Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 25, 2026

Taltz, Eli Lilly’s ixekizumab, uses a low-complexity biologic formulation built around sucrose for stabilization and polysorbate 80 for surface protection. The formulation supports an 80 mg/mL liquid injection in prefilled syringes, autoinjectors, and single-dose vials. The commercial opportunity is concentrated in biosimilar formulation development, excipient and container-closure optimization, device compatibility, and manufacturing-process control rather than in conventional small-molecule generic substitution.

Taltz generated approximately $2.5 billion in global revenue in 2023, making formulation continuity, device performance, and biosimilar substitution risk commercially material for Eli Lilly and potential entrants (Eli Lilly and Company, 2024).

What excipients are used in Taltz?

The U.S. Taltz formulation contains ixekizumab, sucrose, polysorbate 80, and water for injection. The product is a sterile, preservative-free liquid formulation with a target pH in the mildly acidic range.

Component	Function	Commercial relevance
Ixekizumab	Recombinant humanized IgG4 monoclonal antibody targeting IL-17A	Active biological ingredient
Sucrose	Stabilizer and cryoprotectant	Supports protein structure during storage and temperature excursions
Polysorbate 80	Surfactant	Reduces interfacial stress, adsorption, and aggregation
Water for injection	Vehicle	Supports liquid injectable presentation

The formulation’s limited excipient profile reduces manufacturing complexity and simplifies patient exposure analysis. It also creates specific technical risks. Polysorbate 80 can undergo hydrolysis and oxidation, generating degradation products that may affect protein aggregation, particles, and container compatibility. Sucrose supports stability but does not eliminate the need for tight control of temperature, agitation, freeze-thaw exposure, and shipping conditions (U.S. Food and Drug Administration, 2024a).

Why does Taltz use sucrose and polysorbate 80?

Sucrose provides preferential hydration and helps preserve antibody conformation during refrigerated storage and freezing stress. Polysorbate 80 protects the antibody from adsorption to glass, elastomeric components, and air-liquid interfaces.

The combination is common in monoclonal antibody products because it provides stabilization without introducing a large number of formulation variables. The tradeoff is that polysorbate quality, peroxide content, hydrolysis, and supplier consistency become important critical material attributes.

What dosage forms and delivery systems are protected by the Taltz formulation?

Taltz is supplied in several single-dose presentations:

Presentation	Strength	Primary use
Prefilled syringe	80 mg/mL	Patient or healthcare-provider administration
Autoinjector	80 mg/mL	At-home subcutaneous administration
Single-dose vial	80 mg/mL	Healthcare-provider administration

The autoinjector and prefilled syringe create formulation and device dependencies that do not exist in a vial-only product. Viscosity, subvisible particles, silicone oil, needle force, extractables, and dose-delivery accuracy must remain within acceptable ranges throughout shelf life.

The device presentation is commercially important because many patients receive Taltz outside a hospital or clinic. A biosimilar with an equivalent antibody and comparable formulation may still require separate device development, human-factors validation, and combination-product review.

What are the main excipient risks in Taltz manufacturing?

The principal risks are associated with surfactant degradation, protein aggregation, particles, and contact materials.

Polysorbate 80 degradation

Polysorbate 80 can degrade through oxidation or hydrolysis. Risk controls include:

• Low-peroxide excipient specifications
• Supplier qualification and lot testing
• Control of oxygen exposure
• Monitoring of free fatty acids
• Assessment of particle formation
• Compatibility testing with silicone oil and elastomers

Polysorbate degradation can be accelerated by trace metals, light, elevated temperature, and extended storage. A biosimilar sponsor must establish that its excipient grade and manufacturing process do not create a higher impurity or particle burden than the reference product.

Protein aggregation and particles

Ixekizumab is a monoclonal antibody, so aggregation can affect potency, immunogenicity risk, and product quality. The relevant controls include:

• Mixing and hold-time studies
• Pump and filling-line shear assessment
• Freeze-thaw studies
• Shipping simulation
• Visible and subvisible particle testing
• Size-exclusion chromatography
• Light-obscuration and micro-flow imaging
• Charge-variant characterization

Container-closure interaction

The liquid formulation may interact with:

• Silicone oil in prefilled syringes
• Rubber plungers and needle shields
• Tungsten residues from syringe manufacturing
• Extractables and leachables
• Autoinjector-contact materials
• Glass surface treatments

Container-closure optimization is a credible commercial niche because the same antibody formulation can perform differently across syringe, vial, and autoinjector systems.

What formulation patents protect Taltz?

Taltz is a biologic, so its protection is distributed across composition-of-matter, antibody sequence, formulation, manufacturing, therapeutic-use, and delivery-device rights. The U.S. regulatory framework relies on the Purple Book and biologic patent-dispute procedures rather than the small-molecule Orange Book framework.

Public patent databases identify Eli Lilly and related entities as holders of patent families covering ixekizumab antibodies, IL-17A binding, therapeutic uses, and production technologies. Core U.S. patent protection has been reported to extend into the late 2020s, with additional claims potentially reaching beyond the principal biologic term depending on patent type, terminal disclaimers, patent-term adjustment, and enforceability.

A patent review should separate:

1. Antibody sequence claims.
2. Binding-site and epitope claims.
3. Cell-line and expression claims.
4. Purification and manufacturing claims.
5. Formulation claims involving stabilizers and surfactants.
6. Methods for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis.
7. Device and administration claims.

Formulation patents can be commercially relevant even when a biosimilar sponsor designs around the reference antibody patent. A sponsor may use a different surfactant, buffer, sugar, concentration, container, or device, but each change creates comparability and clinical-development work.

When does Taltz lose exclusivity?

Taltz’s U.S. reference-product exclusivity began with FDA approval of BLA 125521 on March 22, 2016. The reference product received 12 years of biologic reference-product exclusivity under the Biologics Price Competition and Innovation Act. That exclusivity period generally prevents FDA approval of a biosimilar application referencing Taltz until March 2028, subject to the specific reference-product calculation and FDA treatment of the application.

Patent expiration is separate from regulatory exclusivity. The principal commercial risk window depends on:

• The earliest enforceable patent expiry.
• Patent-term adjustment.
• Patent-term extension, if available.
• Patent litigation outcomes.
• Biosimilar settlement terms.
• Whether a sponsor launches at risk.
• Whether the biosimilar is interchangeable.

Event	Approximate timing	Commercial effect
Original U.S. BLA approval	March 22, 2016	Starts reference-product exclusivity period
Twelve-year U.S. biologic exclusivity	March 2028	Biosimilar approval pathway becomes available, subject to other barriers
Core patent exposure	Late 2020s and potentially later	Determines lawful launch timing
First potential biosimilar competition	2028 onward	Depends on litigation and settlement outcomes
Broad price erosion	After multiple biosimilars	Usually greater than after a single entrant

The first biosimilar launch may not immediately produce large price declines. Physician familiarity, payer contracting, interchangeability, patient-support programs, and device similarity will influence substitution.

Is Taltz listed in the Orange Book?

Taltz is not an Orange Book-listed small-molecule drug. It is a therapeutic biologic regulated under a biologics license application. Its reference-product and patent information is evaluated through the FDA Purple Book and the BPCIA patent-exchange and litigation framework.

This distinction affects market-entry strategy. A biosimilar sponsor does not file a conventional ANDA with a Paragraph IV certification against Orange Book patents. Instead, it files a 351(k) application and may participate in the BPCIA patent dance. Litigation may proceed under 35 U.S.C. § 271(e)(2) and related provisions, but the process differs from Hatch-Waxman litigation for small molecules.

Which companies are challenging Taltz exclusivity?

No broad commercial biosimilar market for ixekizumab has been established in the United States. Potential challengers include major biologics manufacturers, multinational generic companies with 351(k) capabilities, and specialist biosimilar developers.

The most credible entrants are companies with:

• Monoclonal-antibody analytical platforms
• Established immunogenicity programs
• FDA and EMA biosimilar experience
• Autoinjector and prefilled-syringe capabilities
• Large-scale mammalian-cell manufacturing
• Payer and specialty-pharmacy infrastructure

A biosimilar sponsor must address both the molecule and the delivery system. A vial presentation may offer the fastest route to market, while a prefilled syringe or autoinjector may provide greater commercial value but require more device and human-factors work.

What are the biosimilar risks for Taltz?

Taltz faces biosimilar risk after regulatory exclusivity ends, but its commercial exposure is moderated by several factors.

Formulation similarity

The reference formulation uses a simple excipient system. That makes analytical matching relatively manageable compared with products containing complex buffers, multiple surfactants, or specialized delivery technologies. A sponsor could pursue a close formulation using sucrose and polysorbate 80 or develop a different formulation with a robust comparability package.

Immunogenicity and clinical comparability

The biosimilar must demonstrate no clinically meaningful differences from ixekizumab in quality, biological activity, pharmacokinetics, immunogenicity, and, where required, clinical performance. The sponsor can rely heavily on analytical and pharmacokinetic evidence, but the development program remains costly.

Interchangeability

An interchangeable designation can improve pharmacy-level substitution in the United States, depending on state law and payer policy. A biosimilar without interchangeability may still win contracts through discounts but may face slower switching.

Brand services

Eli Lilly can defend share through:

• Patient copay support
• Specialty-pharmacy distribution
• Nurse injection training
• Autoinjector convenience
• Adherence programs
• Contracting with payers
• Indication-specific positioning

What commercial opportunities exist in Taltz excipients?

The highest-value opportunities are not limited to selling the same excipients used in the reference product.

Low-peroxide polysorbate supply

Excipient suppliers can compete on polysorbate 80 purity, oxidation control, lot consistency, and analytical documentation. A supplier with validated control of peroxide content and fatty-acid composition can target both Lilly and biosimilar manufacturers.

Alternative surfactants

Potential alternatives include polysorbate 20, poloxamer 188, and newer low-degradation surfactant systems. These products may reduce oxidation or hydrolysis risk, but they require full comparability and stability studies. Replacing polysorbate 80 can create a formulation-differentiation opportunity while increasing regulatory burden.

Sugar and stabilizer systems

Sucrose is commercially established, but trehalose and other stabilizers may be evaluated for improved freeze-thaw performance or reduced aggregation. A change in sugar type can affect osmolality, viscosity, glass-transition behavior, and syringe performance.

Antioxidant and chelator strategies

Methionine, histidine, citrate, EDTA, and related systems may be investigated to reduce oxidation or metal-catalyzed degradation. These approaches must be balanced against injection tolerability, pH, regulatory precedent, and protein binding.

Device-compatible formulation platforms

A high-value opportunity is a formulation that performs consistently in:

• Low-dead-volume syringes
• Autoinjectors
• Wearable injectors
• Dual-chamber systems
• Higher-volume subcutaneous delivery devices

Ixekizumab is already concentrated at 80 mg/mL. Further concentration or reduced injection volume could improve patient convenience, but higher concentration can increase viscosity, aggregation, and injection force.

How strong is the Taltz patent estate?

The estate is structurally strong because it can combine biologic sequence claims with use, manufacturing, formulation, and device rights. Its practical strength depends on claim scope and validity rather than patent count alone.

Protection category	Strategic strength	Design-around difficulty
Antibody sequence	High	Very high
IL-17A binding and epitope	High	High
Therapeutic-use claims	Medium to high	Medium
Cell culture and purification	Medium	Medium
Sucrose/polysorbate formulation	Medium	Medium to high
Device presentation	Medium	Medium
Manufacturing process	Variable	Variable

A biosimilar sponsor may avoid some formulation claims by using a different stabilizer system. It cannot easily avoid core molecule claims if the reference antibody sequence remains protected. After core composition claims expire, manufacturing and formulation patents may still delay or complicate entry.

What patent litigation and settlements affect Taltz?

Taltz litigation risk is likely to center on BPCIA patent exchanges, declaratory-judgment actions, infringement claims, validity challenges, and settlement agreements. Publicly available information should be reviewed across:

• FDA Purple Book listings
• U.S. Patent and Trademark Office records
• Federal district court dockets
• Federal Circuit opinions
• SEC filings from Eli Lilly and potential biosimilar sponsors

A settlement may permit an agreed launch date before the latest asserted patent expiration. It may also contain manufacturing, supply, or license provisions. No settlement should be assumed to eliminate all entry restrictions unless the agreement terms are public and enforceable.

What generic launch scenarios exist for Taltz?

Scenario 1: First biosimilar launches near 2028

A first entrant may obtain an early contracting advantage and establish reference pricing. Discounts could be moderate at first because physician and payer adoption will be limited by switching friction.

Scenario 2: Multiple biosimilars launch within two years

Several entrants could create rapid net-price erosion. Payers may use preferred formulary placement to accelerate conversion, particularly in psoriasis and psoriatic arthritis.

Scenario 3: Vial-first entry

A sponsor may launch a vial before developing a patient-friendly autoinjector. This lowers device complexity but limits appeal in home-use markets.

Scenario 4: Interchangeable autoinjector entry

An interchangeable product with a comparable patient experience could create stronger substitution pressure, especially through specialty pharmacies and payer protocols.

How does Taltz compare with competing IL-17 drugs?

Taltz competes primarily with Cosentyx, Tremfya, Bimzelx, Siliq, and other biologic therapies used in psoriasis and related inflammatory diseases.

Product	Active ingredient	Manufacturer	Formulation opportunity
Taltz	Ixekizumab	Eli Lilly	Low-excipient liquid, autoinjector and syringe
Cosentyx	Secukinumab	Novartis	Established subcutaneous biologic platform
Tremfya	Guselkumab	Johnson & Johnson	Device and dosing-convenience competition
Bimzelx	Bimekizumab	UCB	Newer IL-17 pathway competitor
Siliq	Brodalumab	Ortho Dermatologics	IL-17 receptor targeting and safety-positioning differences

Taltz’s excipient simplicity is favorable for biosimilar development, but its commercial defense depends on clinical familiarity, device usability, payer contracts, and the timing of competing IL-17 products.

Key Takeaways

• Taltz uses ixekizumab in a liquid formulation containing sucrose, polysorbate 80, and water for injection.
• The principal formulation risks are polysorbate degradation, protein aggregation, particles, and container-closure interaction.
• Taltz is regulated as a biologic and is not an Orange Book-listed small-molecule product.
• U.S. reference-product exclusivity began with the March 22, 2016, BLA approval and generally reaches the March 2028 period.
• Biosimilar developers can pursue a close formulation or design around the reference excipient system, but each approach creates different comparability and manufacturing risks.
• Commercial opportunities include low-peroxide polysorbate, alternative surfactants, stabilizer systems, syringe compatibility, autoinjector platforms, and analytical testing.
• The strongest barriers are likely to remain the antibody sequence, biologic manufacturing, regulatory comparability, and device integration.
• Taltz’s approximately $2.5 billion 2023 revenue base creates meaningful exposure to biosimilar launch timing and payer-driven substitution.

FAQs

Can a Taltz biosimilar use different excipients?

Yes. A biosimilar may use a different excipient system if the product meets quality, safety, immunogenicity, pharmacokinetic, and regulatory requirements. The sponsor must show that the formulation does not create clinically meaningful differences.

Is polysorbate 80 in Taltz patent-protected by itself?

Polysorbate 80 is a long-established excipient. Commercial protection would generally depend on a specific formulation, concentration, combination, manufacturing process, or product-performance claim rather than ownership of polysorbate 80 as a material.

Can Taltz be reformulated at a higher concentration?

Technically, higher concentration may be possible, but it can increase viscosity, injection force, aggregation, and device requirements. A reformulated product would require extensive analytical, stability, device, and regulatory work.

Do Taltz biosimilars need the same autoinjector?

No. A biosimilar sponsor may use a vial, prefilled syringe, or autoinjector, subject to FDA requirements. A different device can reduce development cost or create differentiation but may weaken substitution convenience.

What is the largest commercial risk to Taltz?

The largest risk is coordinated biosimilar entry after the reference-product exclusivity period, particularly if an interchangeable autoinjector reaches the market and payers use formulary incentives to accelerate switching.

References

1. Eli Lilly and Company. (2024). 2023 annual report.
2. U.S. Food and Drug Administration. (2016). Taltz (ixekizumab) prescribing information.
3. U.S. Food and Drug Administration. (2024a). Taltz (ixekizumab) prescribing information.
4. U.S. Food and Drug Administration. (2024b). Purple Book: Database of licensed biological products.
5. U.S. Food and Drug Administration. (2024c). Questions and answers on biosimilar biological products.
6. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003.
7. U.S. Pharmacopeia. (2024). General chapter <1047>: Gene therapy products and related biologics.